|
|
|
MIRA INFORM REPORT
|
Report No. : |
486456 |
|
Report Date : |
18.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
CARETIUM MEDICAL INSTRUMENTS CO., LIMITED |
|
|
|
|
Registered Office : |
Beishan Industrial
Park, 7th Floor Building 1, Beishan Road, Yantian, Shenzhen, Guangdong
Province 518083 PR |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2016 |
|
|
|
|
Date of Incorporation : |
03.12.2001 |
|
|
|
|
Com. Reg. No.: |
91440300734144898T |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Subject is registered business scope includes importing and exporting commodities and
technology; technology developing, manufacturing and selling Class II 6840
clinical test analysis instrument, and in vitro diagnostic reagent and human
serum inorganic component electrolyte standard substance; and selling Class
II & III |
|
|
|
|
No. of Employees : |
88 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state-support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual liberalization. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi (RMB) after the currency was accepted as part of the IMF’s special drawing rights basket. After engaging in one-way, large-scale intervention to resist appreciation of the RMB for a decade, China’s 2016 intervention in foreign exchange markets has sought to prevent a rapid RMB depreciation that would have negative consequences for the United States, China, and the global economy.
China’s economic growth has slowed since 2011. The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) servicing its high corporate debt burdens to maintain financial stability; (c) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (d) dampening speculative investment in the real estate sector; (e) reducing industrial overcapacity; and (f) raising productivity growth rates through the more efficient allocation of capital. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made only marginal progress toward these rebalancing goals. Under President XI Jinping, Beijing has signaled its understanding that China's long-term economic health depends on giving the market a more decisive role in allocating resources, but has moved slowly on market-oriented reforms because of potential negative consequences for stability and short-term economic growth. He has also increased state-control over key sectors and Party control over state-owned enterprises. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time.
|
Source
: CIA |
COMPANY
NAME and ADDRESS
|
COMPANY NAME |
Caretium Medical Instruments Co., Limited |
|
CURRENT ADDRESS/ REGISTERED ADDRESS |
Beishan Industrial Park, 7th Floor
Building 1, Beishan Road, Yantian, Shenzhen, Guangdong Province 518083 PR
China |
|
TEL. NO. |
86 (0) 755-25273714/25273015 |
|
FAX NO. |
86 (0) 755-25273096 |
EXECUTIVE
SUMMARY
Date of Registration :
december 3, 2001
Unified social credit code : 91440300734144898T
LEGAL FORM : Limited liabilities company
CHIEF EXECUTIVE :
zhang juan (LEGAL REPRESENTATIVE)
REGISTERED CAPITAL :
CNY 20,000,000
staff :
88
BUSINESS CATEGORY :
manufacturing & TRADING
REVENUE :
CNY 46,100,000 (AS OF DEC. 31, 2016)
EQUITIES :
CNY 27,860,000 (AS OF DEC. 31, 2016)
WEBSITE : www.caretium.com
E-MAIL : info@caretium.com
PAYMENT : NO COMPLAINTS
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION :
FAIRly stable
OPERATIONAL TREND : fairly steady
GENERAL REPUTATION :
AVERAGE
Adopted
abbreviations (as follows)
SC - Subject Company (the
company inquired by you)
N/A – Not available
CNY – China Yuan Ren Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This
section aims at indicating the relative positions of SC in respect of its
operational trend & general reputation
Operational
Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly
Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not
known Not
yet be determined
Not
yet be determined
LEGAL
STATUS & HISTORY
SC
was established as a limited liabilities company of PRC with State
Administration of Industry & Commerce (SAIC) under Unified Social Credit
Code: 91440300734144898T.
SC’s Import and Export Enterprise Code:
4403734144898
SC’s registered capital: CNY
20,000,000
SC’s paid-in capital: CNY 20,000,000
Registration Change Record:-
|
Date |
Change of Contents |
Before the change |
After the change |
|
2007-1-29 |
Registered Capital |
CNY 2,000,000 |
CNY 5,000,000 |
|
2008-8-5 |
Registered Capital |
CNY 5,000,000 |
CNY 8,000,000 |
|
2009-2-27 |
Registered Capital |
CNY 8,000,000 |
CNY 10,000,000 |
|
2012-10-23 |
Registered Capital |
CNY 10,000,000 |
CNY 14,000,000 |
|
2016-10-25 |
Registered Capital |
CNY 14,000,000 |
CNY 20,000,000 |
|
-- |
Registration No./ Unified Social Credit Code |
440301103542185 |
91440300734144898T |
Current Co search indicates SC’s shareholders & chief
executives are as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
Zhang Juan |
99.3 |
|
Shen Zichen |
0.7 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative and Chairman |
Zhang Juan |
|
General Manager |
Shen Zichen |
|
Supervisor |
Zhang Wan |
RECENT
DEVELOPMENT
No
recent development was found during our checks at present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
Zhang
Juan 99.3
Shen
Zichen 0.7
MANAGEMENT
Zhang Juan, Legal
Representative and Chairman
-------------------------------------------------------------------------
Gender:
F
Nationality:
China
Working
experience (s):
At
present, working in SC as legal representative and chairman
Shen Zichen, General
Manager
----------------------------------------------------
Gender:
M
Nationality:
China
Working
experience (s):
At
present, working in SC as general manager
Supervisor
--------------
Zhang Wan
BUSINESS
OPERATION
SC’s registered business scope includes
importing and exporting commodities and technology; technology developing, manufacturing
and selling Class II 6840 clinical test analysis instrument, and in vitro
diagnostic reagent and human serum inorganic component electrolyte standard
substance; and selling Class II & III
SC
is mainly engaged in manufacturing and selling medical instruments.
SC’s
products mainly include:
Hematology
analyzer
Electrolyte
analyzer
Biochemistry
analyzerr
Microplate
Reader
Microplate
Washer
ESR
Analyzer
Coagulometer
Urine
Analyzer
Automatic
Biochemistry System
Reagent
Products
utomatic
Glycohemoglobin Analyzer
SC
sources its materials 100% from domestic market. SC sells 60% of its products
in domestic markets and 40% to overseas market.
The
buying terms of SC include Check, T/T and Credit of 30-60 days. The payment
terms of SC include Check, T/T, L/C and Credit of 30-60 days.
*Major
Customer*
-----------------------
Accurex
Biomedical Pvt. Ltd.
Staff & Office:
--------------------------
SC is
known to have approx. 88 staff
at present.
SC
rents an area as its operating office and factory, but the detailed information
is unknown.
RELATED
COMPANY
SC is known to have the
following subsidiary & branch at present,
Nanjing
Xinkaite Bio-tech Development Co., Ltd.
Caretium
Medical Instruments Co., Limited Nanshan Branch
PAYMENT
Overall payment appraisal:
(
) Excellent ( ) Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The
appraisal serves as a reference to reveal SC's payments habits and ability to
pay. It is based on the 3 weighed
factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: SC did not provide any name of trade/service suppliers and we
have no other sources to conduct the enquiry at present.
Delinquent payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for collection within
the last 6 years.
BANKING
The
bank information of SC is not filed in local SAIC.
FINANCIALS
Financial Summary
|
Unit: CNY’000 |
As of Dec. 31, 2016 |
|
Total assets |
44,250 |
|
|
------------- |
|
Total liabilities |
16,390 |
|
Equities |
27,860 |
|
|
------------- |
|
Revenue |
46,100 |
|
Profits |
2,380 |
Important Ratios
=============
|
|
As of Dec. 31, 2016 |
|
*Liabilities to assets |
0.37 |
|
*Net profit margin (%) |
5.16 |
|
*Return on total assets (%) |
5.38 |
|
*Revenue / Total assets |
1.04 |
FINANCIAL
COMMENTS
PROFITABILITY: AVERAGE
The
revenue of SC appears average in its line.
SC’s
net profit margin is average.
SC’s
return on total assets is average.
LIQUIDITY: AVERAGE
SC’s
revenue is in an average level, comparing with the size of its total assets.
LEVERAGE: AVERAGE
The
debt ratio of SC is average.
The
risk for SC to go bankrupt is above average.
Overall financial
condition of the SC: Fairly Stable.
CONCLUSIONS
SC
is considered medium-sized in its line with fairly stable financial conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.98 |
|
|
1 |
INR 88.13 |
|
Euro |
1 |
INR 78.35 |
|
CNY |
1 |
INR 9.92 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
PRA |
|
|
|
|
Report Prepared
by : |
TRU |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.